Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Ciba Ritalin "weak signal" of carcinogenicity in rodent studies subject of Jan. 11 "Dear Doctor" letter.

  • News

Executive Summary

CIBA-GEIGY RITALIN "WEAK SIGNAL" OF CARCINOGENICITY is the subject of a "Dear Doctor" letter mailed by the company Jan. 11. Requested by FDA and based on a report on a pair of two-year rodent studies of methylphenidate in rats and mice by the National Toxicology Program, the letter states that one study in B6C3F1 mice showed "an increase in hepatocellular adenomas (benign tumors) and, in males only, an increase in hepatoblastomas (rare malignant tumors)."

Table

View full table

Tags:
Latest Headlines

Shionogi: Other Countries Must Follow UK’s Lead On Antimicrobial Incentives

Industry Calls For Caution Over EMA Supply Chain Recommendations

Industry Slates Decision To Exempt Parallel Importers From New Danish Stockpile Rules

Asian Industry Groups Push For Universal Care, E-Labeling, Flexible Supply Chain

See All
UsernamePublicRestriction

Register

PS027507

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By